Effects of interferon-alpha2b on hearing.
ABSTRACT The aim of the present study was to investigate the effects of interferon-alpha2b treatment on hearing in patients with chronic active hepatitis B. Twenty-six patients with chronic active hepatitis B were enrolled in the study, and pure-tone audiometry was performed to determine hearing thresholds of the patients before and at the end of 6 months of interferon-alpha2b treatment. There was no significant change in hearing thresholds of patients after treatment with interferon-alpha2b (p>0.05). The results of the present study indicate that interferon-alpha2b therapy does not have any negative effect on hearing thresholds of patients with chronic active hepatitis B. There is a need for further studies involving larger numbers of patients to allow conclusions to be drawn regarding the safety of this therapy with respect to hearing.
- [Show abstract] [Hide abstract]
ABSTRACT: Some reports in the literature have linked interferon therapy for the treatment of hepatitis C (HCV) with hearing loss. The aim of this study has been to examine the effects of interferon therapy on hearing of patients treated for HCV. Patients were recruited according to preset inclusion criteria from two centers. All patients received standard dose pegylated interferon (PEG-IFN a-2b or a-2a) plus ribavirin (RBV). All patients had pure-tone audiometry (PTA), tympanogram and distortion-product otoacoustic emission (DPOAE) before treatment, three months after initiation of treatment, and three months after completion of treatment. Twenty one patients were prospectively recruited. The mean age was 45.7 years. The male to female ratio was 1.1:1. The mean PTA was 15.9 ± 5.3 before treatment, 17.4 ± 6.1 during treatment and 16.5 ± 5.1 after treatment. The differences between pre and mid, pre and post, as well as mid and post were not significantly different (P>0.05) in all audiological assessments. Our results indicate that PEG-IFN\RBV therapy does not have any impact on the hearing thresholds of patients with HCV.Saudi Journal of Gastroenterology 17(2):114-8.